SecBot SecBot
PRESS-RELEASE ·Filed Nov 9, 2026

MTRI

Mentari Therapeutics, Inc.
NEUTRAL
Impact 2/10
Horizonweeks Processed7d 19h ago WireGlobeNewswire
Press release · FDA
Actionable Insight • Neutral

No material news was released; the conferences may provide a venue for pipeline updates. Monitor for any clinical data or partnership announcements that could emerge from these events.

DirectionNeutral
Confidencehigh
Horizonweeks

Drugs in focus

MT-001

● Neutral Named in this press release
Impact
Phase
Preclinical (IND-enabling)
Time to market
Unknown — still preclinical. If successful through Phases 1-3, a potential approval would be 5+ years away.
Next catalyst
None dated

What to watchMT-001 is too early for a binary trade, no human data exists yet and Phase 2a data is two+ years out. The real near-term story for INM is the reverse-merger close (expected by Dec 31, 2026) and whether the $290M PIPE fully funds through 2028 as promised. Post-merger the ticker changes, so current INM holders are effectively buying Mentari's preclinical pipeline at the merged entity's valuation. Watch for the IND/CTA filing mid-2026 as a first proof of life.

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+5
Entry
$16.00
T+0 close · Nov 9, 2026 · via day close
Latest settled
+24.19%
T+5 · $19.87
Vs SPY
+25.88%
α at T+5
Next horizon
T+20
in 21d
  1. T+0 · Nov 9 $16.00entry
  2. T+1 · 7d ago −23.75%α −23.38% · $12.20
  3. T+5 · 20h ago +24.19%α +25.88% · $19.87
  4. T+20 · in 21d Pending
  5. T+60 · in 3mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Mentari Therapeutics announced management participation in three upcoming investor conferences in November 2026. This is a routine investor relations activity with no material financial or clinical data disclosed.

Key Facts

  • Management to present at Guggenheim 3rd Annual Healthcare Innovation Conference on Nov 9, 2026 at 4:00 p.m. ET
  • Management to present at Stifel 2026 Healthcare Conference on Nov 12, 2026 at 10:00 a.m. ET
  • Management to present at 2026 Jefferies Global Healthcare Conference in London on Nov 17, 2026 at 11:00 a.m. GMT
  • Webcasts will be archived on Mentari's website for 90 days following each conference
  • Lead programs are MT-001 (anti-PACAP mAb) and MT-002 (anti-PACAP/anti-CGRP bispecific) for migraine prevention

Financial Impact

No financial data disclosed in the release

Risk Factors

  • No clinical data or financial guidance was provided in this release
  • Investor conferences may not result in material disclosures

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3398334

US Market Status

Market Closed · Opens in 6h 16m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 9, 2026